CORDIS
EU research results

CORDIS

English EN
Point-of-care tests to revolutionise the clinical management of patients infected by Hepatitis C virus

Point-of-care tests to revolutionise the clinical management of patients infected by Hepatitis C virus

Objective

Point-of-care (PoC) medical devices have the potential to revolutionise clinical practice. SMEs within our Consortium (Epistem & Biosurfit) have developed genetic and protein PoC devices to deliver on this promise. Results from these enabling technologies will be integrated using novel bioinformatics tools and algorithms (Qlucore) allowing for bed-side analysis. This integrated genetic-protein approach will exploit recent biomarker discoveries from the FP7 project SPHINX, to improve the management of hepatitis C virus (HCV) infected patients. We will focus on two public health problems: (i) addressing the need to predict, pre-treatment, individuals in resource poor countries (e.g. Egypt) who will benefit from conventional treatment; and (ii) helping to limit treatment costs globally, where new therapies for HCV are anticipated to significantly increase health care expenditures. The predicitve biomarkers are ready for immediate implementation and will greatly improve HCV patient management issues such as decision to treat, selection of therapy, and response-guided monitoring. The predictive power of the SPHINX biomarkers are reliant upon the combination of genetic and protein data. Highlighting the innovative aspect of our proposed work, no clinical algorithms have taken advantage of such a combined genetic / protein biomarker approach for diagnostic tests. To realise this vision, Qlucore will establish patient population-based algorithms that integrate the PoC data on a mobile application, thus facilitating immediate interpretation by physicians. Together, our Consortium will boost prior FP7 discoveries and deliver an integrated platform for predictive and prognostic applications. The associated SMEs will expand their portfolio, but more importantly, our consortium will forge a lasting partnership, formalised by the creation of a new corporation that will have the freedom to market and exploit our collective results.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

Address

Rue De Tolbiac 101
75654 Paris

France

Activity type

Research Organisations

EU Contribution

€ 2 063 193

Administrative Contact

Laurie Louis-Joseph (Ms.)

Participants (4)

Sort alphabetically

Sort by EU Contribution

Expand all

INSERM - TRANSFERT SA

France

EU Contribution

€ 220 120

EPISTEM LTD

United Kingdom

EU Contribution

€ 1 459 738

BIOSURFIT SA

Portugal

EU Contribution

€ 1 393 000

QLUCORE AB

Sweden

EU Contribution

€ 855 375

Project information

Grant agreement ID: 601851

Status

Closed project

  • Start date

    1 September 2013

  • End date

    31 August 2016

Funded under:

FP7-HEALTH

  • Overall budget:

    € 8 034 430

  • EU contribution

    € 5 991 426

Coordinated by:

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France